参考文献/References:
[1]李贺,郑荣寿,张思维,等. 2014年中国女性乳腺癌发病与死亡分析[J]. 中华肿瘤杂志, 2018,40(3):166-171.
[2]Barish R,Lynce F,Unger K,et al. Management of cardiovascular disease in women with breast cancer[J]. Cir culation,2019,139(8):1110-1120.
[3]Upshaw JN. Cardio-oncology:protecting the heart from curative breast cancer treatment[J]. Gland Surg,2018,7(4):350-365.
[4]Thavendiranathan P,Abdel-Qadir H,Fischer HD,et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study[J]. J Clin Oncol, 2016,34(19):2239-2246 .
[5]Almuwaqqat Z,Meisel JL,Barac A,et al. Breast cancer and heart failure[J]. Heart Fail Clin, 2019,15(1):65-75.
[6]Gavila J,Segui MA,Calvo L,et al. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer:a Delphi study[J]. Clin Transl Oncol,2016,19(1):91-104.
[7]Chen YR,Zweier JL. Cardiac mitochondria and reactive oxygen species generation[J]. C irc Res,2014,114(3):524-537.
[8]Smith BD,Bellon JR,Blitzblau R,et al. Radiation therapy for the whole breast:executive summary of an American Society for Radiation Oncology(ASTRO) evidence-based guideline[J]. Pract Radiat Oncol,2018,8(3):145-152.
[9]Bartlett FR,Colgan RM,Donovan EM,et al. The UK HeartSpare Study(Stage IB):randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery[J]. Radiother Oncol,2015,114(1):66-72.
[10]Piroth MD,Petz D,Pinkawa M,et al. Usefulness of a thermoplastic breast bra for breast cancer radiotherapy:a prospective analysis[J]. Strahlenther Onkol,2016,192(9):609-616.
[11]Russell RR,Alexander J,Jain D,et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy[J]. J Nucl Cardiol,2016,23(4):856-884.
[12]Barret-Lee PJ,Dixo JM,Farrel C,et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk[J]. Ann Oncol,2009,20(5):816-827.
[13]Armenian SH,Lacchetti C,Barac A,et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers :American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol,2017,35(8):893-911.
[14]Kalam K,Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy:a systematic review and meta-analysis[J]. E ur J Cancer ,2013,49(13):2900-2909.
[15]Smith LA,Cornelius VR,Plummer CJ,et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials[J]. BMC Cancer ,2010,10(1):337-340.
[16]Franco YL,Vaidya TR,Ait-Oudhia S. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer[J]. Breast Cancer(Dove Med Press),2018,10:131-141.
[17]黄鑫,关旭敏,杨晓蕾,等. 蒽环类药物相关心脏毒性的发病机制 [J].中国医学前沿杂志(电子版),2017,9(9):15-19.
[18]Henriksen PA. Anthracycline cardiotoxicity:an update on mechanisms,monitoring and?prevention[J]. Heart,2017,104(12),971-977.
[19]]Lyu YL,Kerrigan JE,Lin CP,et al. TopoisomeraseⅡmediated DNA double-strand breaks:implications in doxorubicin cardiotoxicity and prevention by dexrazoxane[J].
Cancer Res,2007,67(18):8839-8846.
[20]Drummond DC,Meyer O,Hong K,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors[J]. Pharmacol Rev,2000,51(4):691-743.
[21]Avila MS,Ayub-Ferreira SM,de Barros Wanderley MR Jr ,et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity[J]. J Am Coll Cardiol,2018,71(20):2281-2290.
[22]Daniela C,Vincenzo C,Carlo MC. The breast cancer patient in the cardioncology unit[J]. J Thorac Dis ,2018,10(Suppl 35):S4306-S4322.
[23]Hiona A,Lee AS,Nagendran J,et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function [J]. J Thorac Cardiovasc Surg,2011,142(2):396-403.
[24]Gulati G,Heck SL,Ree AH,et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy(PRADA):a 2×2 factorial,randomized,placebo-controlled, double-blind clinical trial of candesartan and metoprolol[J]. Eur Heart J,2016,37(21):1671-1680.
[25]Gulati G,Heck SL,R?sj? H,et al. Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac Dysfunction during Adjuvant Breast Cancer therapy) study[J]. J Am Heart Assoc,2017,6(11):1-14.
[26]Boekhout AH,Gietema JA,Milojkovic Kerklaan B,et al. AngiotensinⅡ-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer:a randomized clinical trial[J]. JAMA Oncol,2016,2(8):1030-1039.
[27]Henninger C,Fritz G. Statins in anthracycline-induced cardiotoxicity:Rac and Rho,and the heartbreakers[J]. Cell Death Dis,2017,8(1):e2564- e2565.
[28]Calvillo-Argüelles O,Abdel-Qadir H,Michalowska M,et al. Cardioprotective effect of statins in patients with HER2 positive bresst cancer receiving trastuzumab[J]. Can J Cardiol,2019,35(2):153-159.
[29]Seicean S,Seicean A,Plana J,et al.?Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy:an observaiongal clinical cohort study[J]. J Am Coll Cardiol,2012,60(23):2384-2390.
[30]Cote GM,Sawyer DB,Chabner BA. ERBB2 inhibition and heart failure[J]. N Engl J Med,2013,368(9):875-876.
[31]Zeglinski M,Ludke A,Jassal DS,et al. Trastuzumab induced cardiac dysfunction :a “dual-hit” [J]. Exp Clin Cardiol,2011,16(3):70-74.
相似文献/References:
[1]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(1):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[2]戴秋月 郎吉萍 吕萍 潘杭雨 郭志刚.他汀类药物抗乳腺癌作用的研究进展[J].心血管病学进展,2021,(9):776.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
DAI Qiuyue,LANG Jiping,LYU Ping,et al.Effect of Statins Against Breast Cancer[J].Advances in Cardiovascular Diseases,2021,(1):776.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[3]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(1):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[4]郭良 黄鹤.恶性肿瘤相关心房颤动发病机制的研究进展[J].心血管病学进展,2022,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
GUO LiangHUANG He.Pathogenesis of Malignant Tumor-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(1):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
[5]杨仙 陈芸霖 殷跃辉 易鑫 杨敏 崔犇.女性乳腺癌相关性心房颤动的研究现状[J].心血管病学进展,2023,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]
YANG Xian,CHEN Yunlin,YIN Yuehui,et al.Research Status of Female Breast Cancer Associated Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(1):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]